Материал: Идиопатическая тромбоцитопеническая пурпура (рекомендации) 2018 года

26.Stasi R., Brunetti M., Pagano A., Stipa E., Masi M., Amadori S. Pulsed intravenous highdose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol. Dis. 2000; 26(6): 582--6.

27.Mazzuconi M.G., Fazi P., Bemasconi S., De Rossi G., Leone G., Gugliotta L., et al.; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GINEMA experience. Blood. 2007; 109(4): 1401--7.

28.British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br. J. Haematol. 2003; 120(4): 574--96.

29.Khellaf M., Michel M., Schaeffer A., Bierling P., Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005; 90(6) :829--32.

30.Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood. 1984; 64(6): 1179--83.

31.Stasi R., Stipa E., Masi M., Cecconi M., Scimò M.T., Oliva F., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med. 1995; 98(5): 436--42.

32.Godeau B., Chevret S., Varet B., Lefrère F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicenter trial.

Lancet. 2002; 359(9300): 23--9.

46

33.Cheng Y., Wong R.S., Soo Y.O.., Chui CH, Lau FY, Chan NP, et al. Initial treatment of ITP with high-dose dexamethasone. N. Engl. J. Med. 2003; 349(9) :831--6.

34.Lakshman S., Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J. Thromb. Haemost. 2012; 10(10): 1988--98. doi: 10.1111/j.1538-7836.2012.04876.x.

35.Vianelli N., Galli M., de Vivo A., Intermesoli T., Giannini B., Mazzucconi M.G., et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90(1): 72--7.

36.McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004; 104(4): 956--60.

37.Vianelli N., Palandri F., Polverelli N., Stasi R., Joelsson J., Johansson E., et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013; 98(6): 875--80. doi: 10.3324/haematol.2012.075648.

38.Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004; 104(9): 2623--

39.Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood.

2012; 120(5): 960--9. doi: 10.1182/blood-2011-12-309153.

40. Krauth M.T., Lechner K., Neugebauer E.A., Pabinger I. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention -- an unresolved issue. Haematologica.

2008; 93(8): 1227--32. doi: 10.3324/haematol.12682.

47

41.Boyle S., White R.H., Brunson A., Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013; 121(23): 4782--90. doi: 10.1182/blood-2012-12-467068.

42.Newland A., Provan D., Myint S. Preventing severe infection after splenectomy. Br. Med. J. 2005; 331(7514): 417--8.

43.Kuter D.J. New thrombopoietic growth factors. Blood. 2007; 109(11): 4607--16.

44.Arnold D.M., Nazi I., Kelton J.G. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Expert Opin. Investig. Drugs. 2009; 18(6): 805--19. doi: 10.1517/13543780902905848 .

45.Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist. 2009; 14(10): 12-21. doi: 10.1634/theoncologist.2008-0132.

46.Масчан А.А., Румянцев А.Г. Стимуляция продукции тромбоцитов: новый подход к лечению хронической иммунной тромбоцитопенической пурпуры. Онкогематология.

2009; 1: 51--6.

47. Keating G.M. Romiplostim. A review of its use in immune thrombocytopenia. Drugs.

2012; 72(3): 415--35. doi: 10.2165/11208260-000000000-00000.

48. Stasi R., Murali M., Michel M., Viallard J.F., Giagounidis A., Janssens A., et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int. J. Hematol. 2012; 96(1): 26--33. doi: 10.1007/s12185-012-1088-8.

49. Baldini S, Rigacci L, Carrai V, Alterini R, Fjerza R, Bosi A. Patients with ≥ 20 × 10(9)/l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment: an italian single-institution experience. Mediterr J Hematol Infect Dis. 2012;4(1):e2012044. doi: 10.4084/MJHID.2012.044.

48

50. Cines D.B., Gernsheimer T.B., Wasser J., Godeau B., Provan A., Lyons R.M., et al. Integrated analysis of long term safety in patients (pts) with chronic immune thrombocytopenia (ITP) treated with romiplostim. Int J Hematol. 2015 Sep;102(3):259-70. doi: 10.1007/s12185-015-1837-6.51. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia safety and efficasy. Br. J. Haematol. 2013; 161(3): 411-23. doi: 10.1111/bjh.12260.

52.Garnock-Jones K.P., Keam S.J. Eltrombopag. Drugs. 2009; 69(5): 567--76. doi: 10.2165/00003495-200969050-00005.

53.Bussel J.B., Provan D., Shamsi T., Cheng G., Psaila B., Kovaleva L., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet.

2009; 373(9664): 641–8. doi: 10.1016/S0140-6736(09)60402-5.

54.Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393-402. doi: 10.1016/S0140-6736(10)60959-2.

55.Tarantino M.D., Fogarty P., Mayer B., Vasey S.Y., Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul. Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99

56.Bussel J.B., Saleh M.N., Vasey S.Y., Mayer B., Arning M., Stone N.L. Repeated shortterm use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br. J. Haematol. 2013; 160(4): 538--46. doi: 10.1111/bjh.12169.

57.Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., Brainsky A.; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune

49

thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013; 121(3): 537--45. doi: 10.1182/blood-2012-04-425512.

58. Janssens A, Tarantino M, Bird RJ, Mazzucconi MG, Boccia RV, Fernández MF, et al. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. Acta Haematol. 2015;134(4):215-28. DOI: 10.1159/000381657

59.Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009; 113(10): 2161--71. doi: 10.1182/blood-2008-04-150078.

60.Kuter D.J., Rummel M., Boccia R., Macik BG, Pabinger I, Selleslag D, et al. . Romiplostim or standard of care in patients with immune thrombocytopenia. N. Engl. J. Med. 2010;363(20):1889-1899.

61.Shirasugi Y., Ando K., Hashino S., Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int. J. Hematol. 2009 Sep;90(2):157-65. doi: 10.1007/s12185-009-0361-y.

62.Khellaf M., Viallard J.F., Hamidou M., Cheze S., Roudot-Thoraval F., Lefrere F., et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agomists in immune

10.3324/haematol.2012.074633.

63.Patel V.L., Mahevas M., Lee S.Y., Stasi R., Cunningham-Rundles S., Godeau B. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25): 5989--95. doi: 10.1182/blood-2011-11-393975.

64.Keidar A., Sagi B., Szold A. Laparoscopic splenectomy for immune thrombocytopenic purpura in patients with severe refractory thrombocytopenia. Pathophysiol. Haemost. Thromb. 2003; 33(2): 116--9.

50